🧬 First-in-Human Cellular Rejuvenation

ER-100 Reprogramming Trial Dashboard

Life Biosciences — the first FDA-cleared human trial of partial epigenetic reprogramming using Yamanaka factors (OSK) to reverse cellular aging in optic neuropathies
NCT07290244 Phase 1
IND Cleared Jan 28, 2026
Indications OAG + NAION
Delivery AAV Intravitreal
Factors OCT4 · SOX2 · KLF4

A Watershed Moment in Rejuvenation Medicine

On January 28, 2026, Life Biosciences received FDA clearance for the first-ever human clinical trial of cellular rejuvenation via partial epigenetic reprogramming. ER-100 delivers three Yamanaka factors (OCT4, SOX2, KLF4) directly into the eye to restore aged retinal ganglion cells to a younger epigenetic state — without altering DNA sequence.

1st
Human Reprogramming Trial
3
Yamanaka Factors (OSK)
2
Indications (OAG + NAION)
$82M
Series C (2022)
2020
Nature Proof-of-Concept
NHP ✓
Primate Safety + Efficacy

The Thesis: Aging as Epigenetic Information Loss

Young Cell Ordered methylation Tight gene regulation Full regenerative capacity Low epigenetic entropy AGING DNA damage Inflammation Aged Cell Disordered methylation Aberrant gene expression Loss of function High epigenetic entropy ER-100 OSK factors AAV delivery Rejuvenated Cell Restored methylation Youthful gene expression Recovered function Identity preserved ✓ The Information Theory of Aging (Sinclair, 2019) Aging is not primarily caused by genetic mutations, but by the loss of epigenetic information — the "software" that tells cells which genes to express. Like scratches on a CD, epigenetic marks accumulate noise over time, causing cells to forget their identity and function. Partial reprogramming (OSK without c-MYC) acts as a "polishing step" — restoring the original signal without erasing the data. ER-100 is the first test of this theory in human patients.

🏛️ Why This Matters

Since Yamanaka's 2006 Nobel Prize discovery, the longevity field has asked: can we partially reprogram cells to reverse aging without turning them into stem cells (and risking cancer)? After decades of preclinical work — from Ocampo's 2016 Cell paper to Sinclair's 2020 Nature breakthrough — ER-100 is the first therapy to attempt this in humans. If it works, it validates that aging is reversible at the cellular level.

👁️ Why the Eye First?

The eye is the ideal first target for reprogramming therapy: it's an immune-privileged organ (reduced rejection risk), allows direct injection (intravitreal), has quantifiable outcomes (visual acuity, OCT imaging), retinal ganglion cells cannot regenerate naturally, and the eye's small volume limits systemic exposure. Success here opens the door to liver, brain, and systemic applications.

Reprogramming Companies: Funding Landscape

Journey from Discovery to Human Trial

The Science of Partial Epigenetic Reprogramming

Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) can reprogram any cell into a pluripotent stem cell. The key insight behind ER-100: using only three factors (OSK, without c-MYC) reverses epigenetic aging without erasing cell identity — partial reprogramming.

Full Reprogramming (OSKM) vs. Partial Reprogramming (OSK)

Full Reprogramming (OSKM) Somatic Cell Aged, differentiated OSKM Expression All 4 Yamanaka factors iPSC Pluripotent ⚠️ Cell identity LOST → cancer risk (teratoma) ⚠️ c-MYC is a known oncogene ⚠️ Cannot use in living organisms safely Partial Reprogramming (OSK) — ER-100 Aged RGC Damaged, dysfunctional OSK Expression 3 factors, no c-MYC ✓ Young ✓ Cell identity PRESERVED → safe for in vivo use ✓ No oncogene (c-MYC excluded) ✓ Methylation patterns restored to youthful state OCT4 POU5F1 gene Master pluripotency TF Opens chromatin at developmental loci Pioneer factor: binds closed chromatin Initiates demethylation at age-gained CpG sites chr6p21.33 SOX2 SRY-box 2 HMG-box TF Maintains neural stem cell identity Co-binds with OCT4: OCT-SOX composite motif Activates neuronal survival programs chr3q26.33 KLF4 Krüppel-like 4 Zinc-finger TF Context-dependent activator/repressor Anti-apoptotic: cell survival Modulates p21 & cell cycle chr9q31.2 c-MYC — The Excluded Oncogene Drives proliferation and metabolic rewiring. Essential for full iPSC reprogramming, but amplified in ~70% of human cancers. Ohnishi et al. (Cell 2014) showed premature termination of OSKM in vivo → Wilms tumors with altered epigenetic regulation.

🧬 Epigenetic Reprogramming Mechanics

DNA methylation at CpG sites is the primary "software" that tells cells which genes to express. With aging, ~3,000 CpG sites gain or lose methyl groups in predictable patterns (the Horvath clock). OSK factors recruit TET enzymes to actively demethylate age-gained sites while leaving cell-type-specific methylation intact.

5mC → 5hmC TET1/2/3 Recruitment CpG Island Restoration

🔬 Why Partial Works Without Full

Full reprogramming traverses the Waddington landscape "uphill" to the pluripotent summit — erasing cell identity. Partial reprogramming with OSK (especially without c-MYC's proliferative drive) moves the cell partway uphill — enough to reset age-related epigenetic noise, but not enough to lose tissue-specific identity. The cell "rejuvenates in place."

Waddington Landscape Identity Preserved Reversible Process

Epigenetic Clocks: Age Before/After OSK (Preclinical)

Key Reprogramming Milestones

Preclinical Evidence: From Mice to Monkeys

ER-100's path to the clinic rests on landmark preclinical data — first in mice (Lu et al., Nature 2020), then validated in nonhuman primates (NHP) with controlled OSK expression, methylation restoration, and improved visual function.

Landmark Study

Lu et al. Nature 2020

"Reprogramming to recover youthful epigenetic information and restore vision"

  • AAV-delivered OSK to mouse retinal ganglion cells
  • Reversed DNA methylation age in aged mice
  • Restored vision after optic nerve crush injury
  • Reversed glaucoma-related RGC loss in aged mice
  • Effect dependent on TET1/TET2 demethylases
  • No tumor formation observed over 18 months
Evidence strength: Nature, replicated
NHP Validation

Life Bio NHP Studies (2023–2025)

Presented at ARVO 2023, AAO 2024, ARDD 2025

  • Intravitreal AAV-OSK injection in aged NHP
  • Controlled, dose-dependent OSK expression
  • Restoration of youthful methylation patterns
  • Measurable improvement in visual function
  • Acceptable safety and tolerability profile
  • No evidence of tumorigenesis or dedifferentiation
Evidence strength: NHP, company-reported
Foundational

Ocampo et al. Cell 2016

"In vivo amelioration of age-associated hallmarks by partial reprogramming"

  • First in vivo partial reprogramming in progeroid mice (LAKI model)
  • Cyclic OSKM expression (2 days on, 5 days off)
  • Improved tissue function and extended lifespan
  • Established safety of cyclic approach
  • Showed continuous expression → teratoma risk
  • Key lesson: timing and dosing are critical
Evidence strength: Cell, seminal paper

Preclinical-to-Clinical Pipeline

Mouse Studies OSK via AAV2 Optic nerve crush 2018–2020 ✓ NHP Safety Intravitreal injection Dose-range finding 2021–2023 ✓ NHP Efficacy Methylation restoration Visual function ↑ 2023–2025 ✓ IND Filing FDA submission 30-day review Jan 2026 ✓ Phase 1 First patients OAG + NAION Q1 2026 → ~8 years from discovery to first-in-human — fast for gene therapy

OSK Effects in Preclinical Models

Safety Profile: Key Metrics

Phase 1 Clinical Trial Design

NCT07290244 — A Phase 1, open-label, dose-escalation study evaluating the safety, tolerability, immunogenicity, and preliminary efficacy of ER-100 administered by intravitreal injection in patients with optic neuropathies.

NCT07290244
ClinicalTrials.gov
Phase 1
Open-Label, Dose-Escalation
2
Indications (OAG + NAION)
IVT
Intravitreal Injection
Q1 2026
First Patient Expected
28-Day
Dosing Stagger

Trial Architecture

Screening OAG or NAION diagnosis Baseline visual assessment Eligibility confirmation Dose Escalation Cohort 1 Low dose n = 3–6 Cohort 2 Mid dose n = 3–6 Cohort 3 High dose n = 3–6 Follow-Up Safety monitoring Visual assessments Immune response Data MTD/RP2D Phase 2 design Primary Endpoints • Incidence of adverse events (AEs) • Dose-limiting toxicities (DLTs) • Immune response (anti-AAV Ab) • Intraocular inflammation • Systemic biodistribution Focus: SAFETY Secondary Endpoints • Best-corrected visual acuity (BCVA) • Visual field (Humphrey 24-2) • RNFL thickness (OCT imaging) • Pattern ERG (RGC function) • Contrast sensitivity Exploratory: EFFICACY signals Exploratory Endpoints • DNA methylation age (blood) • Aqueous humor biomarkers • Retinal gene expression • OSK transgene expression • Patient-reported outcomes Biomarker: REJUVENATION proof

🏥 Key Design Features

  • 3+3 dose escalation — standard oncology Phase 1 design adapted for gene therapy
  • 28-day stagger — each patient monitored 28 days before next enrollment
  • Single-eye treatment — fellow eye serves as internal control
  • Data Safety Monitoring Board — independent review at each dose level
  • Expected enrollment — 9–18 patients across 3 dose cohorts

⚠️ Key Risk Factors to Watch

  • Anti-AAV antibodies — may limit re-dosing or exclude seropositive patients
  • Intraocular inflammation — common with intravitreal AAV, manageable with steroids
  • Uncontrolled OSK expression — must demonstrate tight regulation in humans
  • Tumorigenicity — long-term monitoring essential (c-MYC excluded but risk exists)
  • Immune response — both innate (inflammation) and adaptive (anti-transgene)

Target Diseases: OAG & NAION

ER-100 targets two optic neuropathies — conditions where retinal ganglion cells (RGCs) irreversibly die, causing permanent vision loss. No disease-modifying therapies exist for either indication.

Open-Angle Glaucoma (OAG)

Chronic Neurodegeneration
Prevalence~80M worldwide (leading cause of irreversible blindness)
MechanismProgressive RGC death ± elevated intraocular pressure (IOP)
Current TxIOP-lowering drops/surgery — does NOT protect RGCs directly
Unmet Need~40% patients progress despite IOP control; normal-tension glaucoma has no treatment
Market$7.8B globally (2025), growing to $11B+ by 2030

NAION ("Stroke of the Eye")

Acute Ischemic Event
Incidence~6,000 new cases/year in US (most common acute optic neuropathy in adults >50)
MechanismSudden ischemia of optic nerve head → acute RGC loss
Current TxNone approved — observation only
Unmet Need100% unmet — no therapy exists to restore lost vision after NAION
PrognosisPermanent vision loss; ~15% risk in fellow eye within 5 years

Retinal Ganglion Cell Biology & ER-100 Mechanism

Retinal Layers Photoreceptors (rods/cones) Bipolar Cells Amacrine / Horizontal Retinal Ganglion Cells ★ Nerve Fiber Layer Optic Nerve Brain ER-100 Intravitreal Injection 1. AAV vector injected into vitreous humor 2. Transduces RGCs via inner limiting membrane 3. OSK expression → epigenetic reprogramming 4. RGCs rejuvenate → axon regeneration + function Why RGCs Cannot Naturally Regenerate Adult mammalian CNS neurons (including RGCs) lose their regenerative capacity after development. Key barriers: intrinsic epigenetic silencing of growth programs, myelin-associated inhibitors (Nogo/MAG/OMgp), glial scarring, and CSPG-rich extracellular matrix. OSK reactivates the developmental gene program — essentially convincing adult RGCs they are young again, restoring their ability to regenerate axons and reconnect to the brain.

Glaucoma: Global Burden & Market

Current Treatment Landscape

Cellular Reprogramming Competitive Landscape

ER-100 is the first reprogramming therapy in human trials, but a well-funded field of competitors approaches from different angles — ex vivo reprogramming, mRNA delivery, small molecules, and whole-organism approaches.

Company Approach Delivery Stage Funding Key Differentiator Risk

Approach Comparison: Capability Radar

Funding by Company ($M)

🏆 Life Bio's Competitive Moat

  • First-mover — only company with FDA-cleared reprogramming IND
  • NHP efficacy data — most competitors still in rodent models
  • David Sinclair's lab pedigree — Nature 2020 foundational IP
  • Eye-first strategy — ideal safety/efficacy proof-of-concept organ
  • Forge Biologics partnership — cGMP manufacturing secured

⚡ Competitive Threats

  • Altos Labs ($3B) — massive funding, multiple tissue targets, Nobel-level team
  • Turn Bio (mRNA) — non-viral delivery avoids AAV immunogenicity entirely
  • Small molecules — if chemical reprogramming works, it's cheaper and scalable
  • NewLimit — T-cell reprogramming may reach clinic via immune therapy path
  • Retro Bio — Sam Altman-backed, combining reprogramming + plasma exchange

Investment Thesis & Risk Assessment

ER-100's success would validate the Information Theory of Aging and unlock a multi-trillion-dollar market for cellular rejuvenation. But gene therapy development carries significant binary risk.

🐂 Bull Case

  • Platform validation — if ER-100 shows safety + any efficacy signal, it validates partial reprogramming for ALL age-related diseases
  • First-mover in $1T+ TAM — reversing aging is the largest addressable market in medicine
  • Orphan drug potential — NAION has zero approved treatments, fast regulatory path
  • Pipeline optionality — liver, brain, and systemic programs in development
  • Acquisition target — Roche, Novartis, and Regeneron all have AAV gene therapy platforms
  • SingHealth Duke-NUS partnership — Asian market access via Singapore collaboration

🐻 Bear Case

  • Binary Phase 1 risk — safety signal could halt the entire program
  • AAV limitations — pre-existing immunity, immunogenicity, one-shot dosing constraint
  • Long-term cancer risk — continuous OSK expression concerns require years of monitoring
  • Cash runway — private biotech with $82M Series C (2022); likely needs additional funding
  • Competitive moat erosion — mRNA/small molecule approaches may leapfrog AAV delivery
  • Translation gap — mouse/NHP ≠ human; many gene therapies fail in Phase 1

Key Milestone Timeline

Jan 2022
Series C: $82M
Led by undisclosed investors; funds IND-enabling studies and clinical development
Apr 2023
ARVO NHP Data
Restoration of visual function in nonhuman primates; first NHP proof-of-concept
May 2023
Forge Biologics Manufacturing Partnership
cGMP AAV manufacturing secured for clinical supply
Oct 2024
AAO Presentation
Updated NHP data showing safety and efficacy at American Academy of Ophthalmology
Jul 2025
SingHealth Duke-NUS Collaboration
Partnership to expand pipeline of cellular rejuvenation therapies (Singapore)
Aug 2025
ARDD 2025: Liver + Ocular Data
New data on reprogramming platform in liver disease models; pipeline expansion signal
Jan 28, 2026
FDA IND Clearance 🎯
First-ever cellular rejuvenation therapy cleared for human clinical trials — historic milestone
Q1 2026
First Patient Dosed (Expected)
Phase 1 enrollment begins; first human ever treated with epigenetic reprogramming
2027 (Projected)
Phase 1 Data Readout
Safety profile + preliminary efficacy signals; determines Phase 2 design
2028+ (Projected)
Phase 2 + Pipeline Expansion
Dose optimization in OAG/NAION; potential IND for liver/brain indications

Funding History ($M)

Risk Assessment Radar

References

Primary sources, peer-reviewed publications, and regulatory filings supporting this dashboard.

  1. Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature 588, 124–129 (2020). doi:10.1038/s41586-020-2975-4
  2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006). doi:10.1016/j.cell.2006.07.024
  3. Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 167, 1719–1733.e12 (2016). doi:10.1016/j.cell.2016.11.052
  4. Ohnishi K, Semi K, Yamamoto T, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 156, 663–677 (2014). doi:10.1016/j.cell.2014.01.005
  5. Sinclair DA, LaPlante MD. Lifespan: Why We Age — and Why We Don't Have To. Simon & Schuster (2019).
  6. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115 (2013). doi:10.1186/gb-2013-14-10-r115
  7. Yang JH, Hayano M, Griffin PT, et al. Loss of epigenetic information as a cause of mammalian aging. Cell 186, 305–326.e27 (2023). doi:10.1016/j.cell.2022.12.027
  8. López-Otín C, Blasco MA, Partridge L, et al. Hallmarks of aging: An expanding universe. Cell 186, 243–278 (2023). doi:10.1016/j.cell.2022.11.001
  9. Life Biosciences. FDA Clearance of IND Application for ER-100 in Optic Neuropathies. Press Release, January 28, 2026. lifebiosciences.com
  10. ClinicalTrials.gov. NCT07290244: Phase 1 Study of ER-100 in Optic Neuropathies. clinicaltrials.gov
  11. Life Biosciences. NHP Data Presentation at ARVO 2023: Restoration of Visual Function in Nonhuman Primates. April 2023.
  12. Life Biosciences. Presentation at AAO 2024: Progress of NHP Studies Evaluating Partial Epigenetic Reprogramming. October 2024.
  13. Life Biosciences. New Data at ARDD 2025 on Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases. August 2025.
  14. Sen P, Shah PP, Nativio R, Berger SL. Epigenetic mechanisms of longevity and aging. Cell 166, 822–839 (2016). doi:10.1016/j.cell.2016.07.050
  15. Browder KC, Reddy P, Yamamoto M, et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nat. Aging 2, 243–253 (2022). doi:10.1038/s43587-022-00183-2
  16. Gill D, Parry A, Santos F, et al. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. eLife 11, e71624 (2022). doi:10.7554/eLife.71624
  17. Goldberg JL, Klassen MP, Hua Y, Barres BA. Amacrine-signaled loss of intrinsic axon growth ability by retinal ganglion cells. Science 296, 1860–1864 (2002).
  18. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology 121, 2081–2090 (2014). doi:10.1016/j.ophtha.2014.05.013
  19. Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 123, 103–107 (1997).
  20. Life Biosciences & Forge Biologics. cGMP Manufacturing Partnership for Novel Gene Therapies. Press Release, May 2023. lifebiosciences.com